Immunome Inc. cotiza a 17.20 USD y tiene una capitalización bursátil de $2.0B. En los últimos 12 meses ha facturado $0 con un margen de flujo de caja libre del -2890.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clini…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | — | $-0.76 | $-0.65 |
| Estimado | $-0.59 | $-0.50 | $-0.57 | $-0.54 |
| Sorpresa | — | — | -33.3% | -20.4% |
| Métrica | IMNM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -3228.8% | -38.6% | -3190.2% |
| Net Margin | -3060.0% | -33.6% | -3026.4% |
| FCF Margin | -2890.1% | -13.9% | -2876.3% |
| ROE | -33.5% | -40.4% | +6.9% |
| ROA | -31.1% | -32.0% | +0.9% |
| Current Ratio | 14.69 | 2.84 | +11.85 |
| Debt / Equity | — | 0.28 | — |